The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Canrenoic acid     3-[(8R,9S,10R,13S,14S,17R)- 17-hydroxy-10...

Synonyms: Canrenoate, AC1LCVAJ, SureCN636758, BSPBio_000256, CHEBI:50156, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Canrenoate


Psychiatry related information on Canrenoate


High impact information on Canrenoate

  • METHODS: Heart rate variability and baroreflex sensitivity were examined 30 min following the administration of potassium canrenoate (intravenous) (aldosterone antagonist) or saline (control) [7].
  • Cortisol levels, however, were significantly higher after canrenoate, compared with placebo, whereas ACTH and hGH concentrations did not differ [8].
  • Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans [9].
  • Canrenoate (200 mg, iv) or RU486 (400 mg, orally) was administered 150 min before a KCl load (1 mmol/kg BW, orally) in seven healthy males undergoing maximal water diuresis [10].
  • However, canrenoate blunted the kaliuresis after the KCl load (51.9 +/- 4.4 mmol/5 h; P < 0.05 compared to KCl alone) and stimulated natriuresis in a complementary way [10].

Chemical compound and disease context of Canrenoate


Biological context of Canrenoate


Anatomical context of Canrenoate


Associations of Canrenoate with other chemical compounds


Gene context of Canrenoate

  • Pituitary-adrenocortical responsiveness during early sleep was disinhibited after canrenoate which is a selective blocker of mineralocorticoid receptors (MR) located primarily in limbic-hippocampal structures [29].
  • In canrenoate-treated rats, the effect of OPC-31260 was significantly reduced, and semiquantiative immunoblotting demonstrated a significant reduction (45%) in AQP2 expression [24].
  • On radioreceptor assay, plasma from mice chronically administered spironolactone contained approximately 10 times higher levels of androgen receptor active material than from mice administered potassium canrenoate [19].
  • In canrenoate-treated rats, ANP infusion caused greater increases in sodium excretion (FENA from 3.05 +/- 0.71 to 7.21 +/- 0.45%; P < 0.05; n = 8) than saline infusion (FENA from 4.16 +/- 1.11 to 5.47 +/- 0.66%; n = 6), despite the hypocapnia [30].
  • We conclude that long-term therapy with the aldosterone-receptor blocker, potassium canrenoate, can normalize the aldo/PRA ratio in many cases of idiopathic primary hyperaldosteronism after one-month withdrawal of the drug [12].

Analytical, diagnostic and therapeutic context of Canrenoate


  1. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver. Francavilla, A., Di Leo, A., Eagon, P.K., Polimeno, L., Guglielmi, F., Fanizza, G., Barone, M., Starzl, T.E. Gastroenterology (1987) [Pubmed]
  2. Spironolactone- and canrenone-induced changes in hepatic (Na+,K+)ATPase activity, surface membrane cholesterol and phospholipid, and fluorescence polarization in the rat. Miner, P.B., Sneller, M., Crawford, S.S. Hepatology (1983) [Pubmed]
  3. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. Bos, R., Mougenot, N., Médiani, O., Vanhoutte, P.M., Lechat, P. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  4. Effects of canrenoate on red cell sodium transport and calf flow in essential hypertension. Semplicini, A., Buzzaccarini, F., Ceolotto, G., Marzola, M., Mozzato, M.G., Giusto, M., Campagnolo, M., Simonella, C., Pessina, A.C. Am. J. Hypertens. (1993) [Pubmed]
  5. Blocking of central nervous mineralocorticoid receptors counteracts inhibition of pituitary-adrenal activity in human sleep. Born, J., Steinbach, D., Dodt, C., Fehm, H.L. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  6. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Born, J., DeKloet, E.R., Wenz, H., Kern, W., Fehm, H.L. Am. J. Physiol. (1991) [Pubmed]
  7. Acute aldosterone antagonism improves cardiac vagal control in humans. Fletcher, J., Buch, A.N., Routledge, H.C., Chowdhary, S., Coote, J.H., Townend, J.N. J. Am. Coll. Cardiol. (2004) [Pubmed]
  8. Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. Wellhoener, P., Born, J., Fehm, H.L., Dodt, C. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  9. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. Arvat, E., Maccagno, B., Giordano, R., Pellegrino, M., Broglio, F., Gianotti, L., Maccario, M., Camanni, F., Ghigo, E. J. Clin. Endocrinol. Metab. (2001) [Pubmed]
  10. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans. van Buren, M., Boer, P., Koomans, H.A. J. Clin. Endocrinol. Metab. (1993) [Pubmed]
  11. Potassium canrenoate in the treatment of long-term digoxin-induced arrhythmias in conscious dogs. deGuzman, N.T., Yeh, B.K. Am. J. Cardiol. (1975) [Pubmed]
  12. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. Armanini, D., Scaroni, C., Mattarello, M.J., Fiore, C., Albiger, N., Sartorato, P. J. Endocrinol. Invest. (2005) [Pubmed]
  13. Effects on tissue and electrolytes of a mineralocorticoid blocker during DOCA-induced potassium depletion. Levine, D.Z., Sarkar, K. Can. J. Physiol. Pharmacol. (1976) [Pubmed]
  14. Effects of captopril and of other antihypertensive drugs on cell membrane ion transport--a preliminary report. Niutta, E., Tripodi, M.G., Cusi, D., Pati, C., Dossi, F., Elli, A., Bianchi, G. Postgraduate medical journal. (1986) [Pubmed]
  15. Canrenoate disposition in dogs. Tissue distribution and elimination. Kuhlmann, J., Kötter, V., Rietbrock, N. Naunyn Schmiedebergs Arch. Pharmacol. (1977) [Pubmed]
  16. Clinical study of potassium canrenoate on raised intracranial pressure. Node, Y., Nakazawa, S. Advances in neurology. (1990) [Pubmed]
  17. DNA damage in tissues of rat treated with potassium canrenoate. Martelli, A., Carrozzino, R., Mattioli, F., Bucci, G., Lamarino, G., Brambilla, G. Toxicology (2002) [Pubmed]
  18. The acute effects of amiloride and potassium canrenoate on digoxin-induced positive inotropism in healthy volunteers. Richter, J.P., Sommers, D.K., Snyman, J.R., Millard, S.M. Eur. J. Clin. Pharmacol. (1993) [Pubmed]
  19. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Armanini, D., Karbowiak, I., Goi, A., Mantero, F., Funder, J.W. Clin. Endocrinol. (Oxf) (1985) [Pubmed]
  20. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. Bos, R., Mougenot, N., Findji, L., Médiani, O., Vanhoutte, P.M., Lechat, P. J. Cardiovasc. Pharmacol. (2005) [Pubmed]
  21. The difference in endocochlear and endolymphatic sac d.c. potentials in response to furosemide and canrenoate as diuretics. Mori, N., Uozumi, N., Yura, K., Sakai, S. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. (1990) [Pubmed]
  22. Ototoxic effect of potassium canrenoate on the guinea pig cochlea. Komune, S., Wakizono, S., Nakagawa, T., Kimituki, T., Hisashi, K., Uemura, T. Acta Otolaryngol. (1991) [Pubmed]
  23. Lymphocyte function tests in cirrhotic patients under treatment with spironolactone and potassium canrenoate. Cuppone, R., Del Vecchio, S., Zanninelli, G., Delle Monache, M., Ulissi, A., Tavanti, A., Angeloni, A., Ricci, G.L. J. Int. Med. Res. (1988) [Pubmed]
  24. Decreased vasopressin-mediated renal water reabsorption in rats with chronic aldosterone-receptor blockade. Jonassen, T.E., Promeneur, D., Christensen, S., Petersen, J.S., Nielsen, S. Am. J. Physiol. Renal Physiol. (2000) [Pubmed]
  25. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Young, M., Funder, J. Endocrinology (2003) [Pubmed]
  26. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone. Datta, P., Dasgupta, A. Therapeutic drug monitoring. (2003) [Pubmed]
  27. Antihypertensive effect of captopril, canrenoate potassium, and atenolol. Relations with red blood cell sodium transport and renin. Niutta, E., Cusi, D., Colombo, R., Tripodi, G., Pellizzoni, M., Pati, P., Cesana, B., Alberghini, E., Barlassina, C., Bianchi, G. Am. J. Hypertens. (1988) [Pubmed]
  28. Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis. Omland, E., Mathisen, O. Scand. J. Gastroenterol. (1991) [Pubmed]
  29. Hypothalamus-pituitary-adrenal activity during human sleep: a coordinating role for the limbic hippocampal system. Born, J., Fehm, H.L. Exp. Clin. Endocrinol. Diabetes (1998) [Pubmed]
  30. Inhibitory effect of aldosterone on the natriuretic response to atrial natriuretic peptide in hypocapnic rats. Kanauchi, H., Mimura, Y. Clin. Exp. Pharmacol. Physiol. (1998) [Pubmed]
  31. Identification of some human urinary metabolites of orally administered potassium canrenoate by stable isotope-labeling techniques. Vose, C.W., Boreham, D.R., Ford, G.C., Haskins, N.J., Palmer, R.F. Drug Metab. Dispos. (1979) [Pubmed]
  32. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography. Krause, W., Karras, J., Jakobs, U. J. Chromatogr. (1983) [Pubmed]
WikiGenes - Universities